The small molecule drug developer, co-founded by a UCLA associate professor, has completed its series B round.

Octant Bio, a US-based small molecule therapeutics developer co-founded by Sri Kosuri, an associate professor at University of California, Los Angeles (UCLA), has secured $80m in its series B round. Life sciences investment firm Catalio Capital Management led the round, which also featured pharmaceutical firm Bristol Myers Squibb (BMS), boutique investment bank Allen & Company and…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.

Robert Lavine

Robert Lavine is special features editor for Global Venturing.